Journal of Aerosol Medicine and Pulmonary Drug Delivery

Editor-in-Chief: Thomas G. O’Riordan, MD, MPH

ISSN: 1941-2711 | Online ISSN: 1941-2703 | Published Bimonthly | Current Volume: 37

Impact Factor: 3.4* *2022 Journal Citation Reports™ (Clarivate, 2023)

CiteScore™: 5.8

The only peer-reviewed journal delivering innovative, authoritative coverage of the health effects of inhaled aerosols and delivery of drugs through the pulmonary system.

Search Subscribe/Renew Recommend This Title Sign Up for TOC Alerts View Submission Instructions Share with a Colleague

Announcements

RFS Awards in Science Winner

Mary Ann Liebert, Inc., in partnership with the Rosalind Franklin Society launched a prestigious annual award to recognize outstanding published peer-reviewed research by women and underrepresented minorities in science in each of the publisher’s peer-reviewed journals. The RFS Awards in Science for Journal of Aerosol Medicine and Pulmonary Drug Delivery has selected Rachel K. Redmann, BSE who co-authored Particle Dynamics and Bioaerosol Viability of Aerosolized Bacillus Calmette-Guérin Vaccine Using Jet and Vibrating Mesh Clinical Nebulizers.

View RFS Awards in Science Book

Aims & Scope

Journal of Aerosol Medicine and Pulmonary Drug Delivery is the only peer-reviewed journal delivering innovative, authoritative coverage of the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. The Journal is a forum for leading experts, addressing novel topics such as aerosolized chemotherapy, aerosolized vaccines, methods to determine toxicities, and delivery of aerosolized drugs in the intubated patient.

Journal of Aerosol Medicine and Pulmonary Drug Delivery coverage includes:

Pulmonary drug delivery
Airway reactivity and asthma treatment
Inhalation of particles and gases in the respiratory tract
Toxic effects of inhaled agents
Aerosols as tools for studying basic physiologic phenomena

Journal of Aerosol Medicine and Pulmonary Drug Delivery is under the editorial leadership of Editor-in-Chief Thomas G. O’Riordan, MD, MPH, Vice President US Medical and Therapy Head for Respiratory at GlaxoSmithKline and other leading investigators. View the entire editorial board.

Audience: Respiratory specialists, pulmonary specialists, internal medicine specialists, pharmaceutical researchers, and equipment manufacturers, among others.

Indexing/Abstracting:

PubMed/MEDLINE
PubMed Central
Scopus
Current Contents®/Clinical Medicine
Journal Citation Reports/Science Edition
Prous Science Integrity®
EMBASE/Excerpta Medica
Chemical Abstracts
ProQuest databases
BenchSci

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.